Dupilumab for the Management of Moderate-to-Severe Atopic Dermatitis in Pediatric Patients in Chile: A Series of 10 Clinical Cases

Atopic dermatitis (AD) is a common chronic inflammatory disease with a variable course, particularly prevalent in the pediatric population. Targeted therapies-such as monoclonal antibodies (mAbs) and Janus kinase (JAK) inhibitors-represent emerging treatment options. Dupilumab was the first mAb approved by the U.S. Food and Drug Administration (FDA) for the treatment of severe AD. Aim: To describe a case series of patients under 12 years of age with moderate-to-severe AD treated with dupilumab, and to provide practical considerations for its clinical use. Methods: A multicenter, retrospective, descriptive observational study was conducted, including pediatric patients with moderate-to-severe AD treated with dupilumab. Demographic, clinical, and treatment response variables were collected. Results: Ten patients with moderate-to-severe AD (mean baseline EASI score of 24.4 [SD 12]) and a history of prior treatment failure were included. A mean reduction of 13.5 points in EASI score [range: 5.9-25.8] was observed after 6 months of treatment, along with a sustained decrease in individual scores over time. Follow-up duration ranged from 12 to 24 months. Reported adverse effects were mild and did not lead to treatment discontinuation. Conclusions: The findings of this study are consistent with existing literature supporting the efficacy and safety of dupilumab in children under 12 years of age with moderate-to-severe AD. Furthermore, the study provides practical guidance for its use in real-world clinical settings.